腫瘍随伴性小脳変性症（PCD）の世界市場とCOVID-19影響分析：診断別、治療別、エンドユーザー別、地域別－業界分析、市場規模、市場シェア、予測（2022年～2028年）

世界の腫瘍随伴性小脳変性症（PCD）の市場規模は、2022年から2028年までの予測期間中に4.8%のCAGRで成長すると予測されています。

当レポートでは、世界の腫瘍随伴性小脳変性症（PCD）市場について調査分析し、市場概要、市場動向、市場分析、ベンダー分析など、体系的な情報を提供しています。

目次

第1章 腫瘍随伴性小脳変性症（PCD）市場概要

第2章 エグゼクティブサマリー

• 市場の内訳
  • 市場の内訳：診断別
  • 市場の内訳：治療別
  • 市場の内訳：エンドユーザー別
  • 市場の内訳：国別
  • 市場の内訳：地域別
• 競合考察

第3章 腫瘍随伴性小脳変性症（PCD）の主要な市場動向

• 市場促進要因
  • 市場促進要因の影響分析
• 市場抑制要因
  • 市場抑制要因の影響分析
• 市場機会
• 市場の将来の動向

第4章 腫瘍随伴性小脳変性症（PCD）業界調査

• PEST分析
• ポーターのファイブフォース分析
• 成長展望のマッピング
• 規制の枠組み分析

第5章 腫瘍随伴性小脳変性症（PCD）市場：COVID-19影響分析

• COVID-19以前の影響分析
• COVID-19以後の影響分析

第6章 腫瘍随伴性小脳変性症（PCD）市場情勢

• 市場シェア分析（2021年）
• 内訳データ：主要メーカー別
  • 既存企業の分析
  • 新興企業の分析

第7章 腫瘍随伴性小脳変性症（PCD）市場：診断別

• 概要

第8章 腫瘍随伴性小脳変性症（PCD）市場：治療別

• 概要

第9章 腫瘍随伴性小脳変性症（PCD）市場：エンドユーザー別

• 概要

第10章 腫瘍随伴性小脳変性症（PCD）市場：地域別

• イントロダクション
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東とアフリカ

第11章 ベンダー分析

• 競合ダッシュボード
• 企業プロファイル
  • Novartis AG
  • Astellas Pharma Inc.
  • Abbott
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc
  • Glaxosmithkline Plc
  • F. Hoffmann-La Roche Ltd
  • Merck Sharp &Dohme Corp.
  • Sanofi
  • Pfizer Inc.
  • Takeda Pharmaceutical
  • Koninklijke Philips NV
  • General Electric Company
  • Esaote SpA
  • NeuroLogica Corporation
  • Masimo
  • York Instruments Ltd.
  • Neusoft Medical Systems
  • CANON MEDICAL SYSTEMS CORPORATION

第12章 アナリストの全方位的展望

第13章 付録

List of Tables

• TABLE List of data sources
• TABLE Market drivers; Impact Analysis
• TABLE Market restraints; Impact Analysis
• TABLE Paraneoplastic Cerebellar Degeneration (PCD) Market: Diagnosis Snapshot (2021)
• TABLE Segment Dashboard; Definition and Scope, by Diagnosis
• TABLE Global Paraneoplastic Cerebellar Degeneration (PCD) Market, by Diagnosis 2017-2028 (USD Million)
• TABLE Paraneoplastic Cerebellar Degeneration (PCD) Market: Treatment Snapshot (2021)
• TABLE Segment Dashboard; Definition and Scope, by Treatment
• TABLE Global Paraneoplastic Cerebellar Degeneration (PCD) Market, by Treatment 2017-2028 (USD Million)
• TABLE Paraneoplastic Cerebellar Degeneration (PCD) Market: Regional snapshot (2021)
• TABLE Paraneoplastic Cerebellar Degeneration (PCD) Market: End User Snapshot (2021)
• TABLE Segment Dashboard; Definition and Scope, by End User
• TABLE Global Paraneoplastic Cerebellar Degeneration (PCD) Market, by End User 2017-2028 (USD Million)
• TABLE Segment Dashboard; Definition and Scope, by Region
• TABLE Global Paraneoplastic Cerebellar Degeneration (PCD) Market, by Region 2017-2028 (USD Million)
• TABLE North America Paraneoplastic Cerebellar Degeneration (PCD) Market, by Country, 2017-2028 (USD Million)
• TABLE North America Paraneoplastic Cerebellar Degeneration (PCD) Market, by Diagnosis, 2017-2028 (USD Million)
• TABLE North America Paraneoplastic Cerebellar Degeneration (PCD) Market, by Treatment, 2017-2028 (USD Million)
• TABLE North America Paraneoplastic Cerebellar Degeneration (PCD) Market, by End User, 2017-2028 (USD Million)
• TABLE Europe Paraneoplastic Cerebellar Degeneration (PCD) Market, by Country, 2017-2028 (USD Million)
• TABLE Europe Paraneoplastic Cerebellar Degeneration (PCD) Market, by Diagnosis, 2017-2028 (USD Million)
• TABLE Europe Paraneoplastic Cerebellar Degeneration (PCD) Market, by Treatment, 2017-2028 (USD Million)
• TABLE Europe Paraneoplastic Cerebellar Degeneration (PCD) Market, by End User, 2017-2028 (USD Million)
• TABLE Asia Pacific Paraneoplastic Cerebellar Degeneration (PCD) Market, by Country, 2017-2028 (USD Million)
• TABLE Asia Pacific Paraneoplastic Cerebellar Degeneration (PCD) Market, by Diagnosis, 2017-2028 (USD Million)
• TABLE Asia Pacific Paraneoplastic Cerebellar Degeneration (PCD) Market, by Treatment, 2017-2028 (USD Million)
• TABLE Asia Pacific Paraneoplastic Cerebellar Degeneration (PCD) Market, by End User, 2017-2028 (USD Million)
• TABLE Latin America Paraneoplastic Cerebellar Degeneration (PCD) Market, by Country, 2017-2028 (USD Million)
• TABLE Latin America Paraneoplastic Cerebellar Degeneration (PCD) Market, by Diagnosis, 2017-2028 (USD Million)
• TABLE Latin America Paraneoplastic Cerebellar Degeneration (PCD) Market, by Treatment, 2017-2028 (USD Million)
• TABLE Latin America Paraneoplastic Cerebellar Degeneration (PCD) Market, by End User, 2017-2028 (USD Million)
• TABLE Middle East and Africa Paraneoplastic Cerebellar Degeneration (PCD) Market, by Country, 2017-2028 (USD Million)
• TABLE Middle East and Africa Paraneoplastic Cerebellar Degeneration (PCD) Market, by Diagnosis, 2017-2028 (USD Million)
• TABLE Middle East and Africa Paraneoplastic Cerebellar Degeneration (PCD) Market, by Treatment, 2017-2028 (USD Million)
• TABLE Middle East and Africa Paraneoplastic Cerebellar Degeneration (PCD) Market, by End User, 2017-2028 (USD Million)

List of Figures

• FIGURE Paraneoplastic Cerebellar Degeneration (PCD) Market Segmentation
• FIGURE Market research methodology
• FIGURE Value chain analysis
• FIGURE Porter's Five Forces Analysis
• FIGURE Market Attractiveness Analysis
• FIGURE COVID-19 Impact Analysis
• FIGURE Pre & Post COVID-19 Impact Comparision Study
• FIGURE Competitive Landscape; Key company market share analysis, 2021
• FIGURE Diagnosis segment market share analysis, 2021 & 2028
• FIGURE Diagnosis segment market size forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE Treatment segment market share analysis, 2021 & 2028
• FIGURE Treatment segment market size forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE End User segment market share analysis, 2021 & 2028
• FIGURE End User segment market size forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE Regional segment market share analysis, 2021 & 2028
• FIGURE Regional segment market size forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE North America Paraneoplastic Cerebellar Degeneration (PCD) Market share and leading players, 2021
• FIGURE Europe Paraneoplastic Cerebellar Degeneration (PCD) Market share and leading players, 2021
• FIGURE Asia Pacific Paraneoplastic Cerebellar Degeneration (PCD) Market share and leading players, 2021
• FIGURE Latin America Paraneoplastic Cerebellar Degeneration (PCD) Market share and leading players, 2021
• FIGURE Middle East and Africa Paraneoplastic Cerebellar Degeneration (PCD) Market share and leading players, 2021
• FIGURE North America market share analysis by country, 2021
• FIGURE U.S. Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE Canada Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE Europe Paraneoplastic Cerebellar Degeneration (PCD) Market share analysis by country, 2021
• FIGURE Germany Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE Spain Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE Italy Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE France Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE UK Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE Russia Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE Netherlands Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE Sweden Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE Poland Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE Rest of the Europe Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE Asia Pacific Paraneoplastic Cerebellar Degeneration (PCD) Market share analysis by country, 2021
• FIGURE India Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE China Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE Japan Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE South Korea Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE Australia Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE Thailand Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE Indonesia Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE Phillipines Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE Rest of APAC Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE Latin America Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE Latin America Paraneoplastic Cerebellar Degeneration (PCD) Market share analysis by country, 2021
• FIGURE Brazil Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE Mexico Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE Argentina Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE Colombia Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE Rest of LATAM Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE Middle East and Africa Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE Middle East and Africa Paraneoplastic Cerebellar Degeneration (PCD) Market share analysis by country, 2021
• FIGURE Saudi Arabia Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE United Arab Emirates Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE Israel Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE Turkey Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE Algeria Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE Egypt Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)
• FIGURE Rest of MEA Paraneoplastic Cerebellar Degeneration (PCD) Market size, forecast and trend analysis, 2017 to 2028 (USD Million)

REPORT HIGHLIGHT

Paraneoplastic Cerebellar Degeneration (PCD) Market size was valued at USD XX Million in 2021, expanding at a CAGR of 4.8% from 2022 to 2028.

One of the most prevalent paraneoplastic neurological diseases is paraneoplastic cerebellar degeneration, a neurological illness. Immune-mediated damage to cerebellar Purkinje cells is the root cause. It has connections to many cancers, but particularly to pelvic and breast cancers. Additionally, patients with Hodgkin lymphoma, gastric cancer, prostate cancer, and small cell lung cancer exhibit paraneoplastic cerebellar degeneration (PCD).

Market Dynamics

There is a high prevalence of cancer patients across the globe, particularly those with breast, ovarian, and lung cancer, who make up the majority of the target patient group for paraneoplastic cerebellar degeneration (PCD), which is a key factor in the paraneoplastic cerebellar degeneration (PCD) market growth. Middle-aged and older individuals are more affected by the paraneoplastic cerebellar degeneration (PCD) condition because they are more likely to develop cancers like breast, lung, and ovarian. However, neither a permanent cure nor a targeted treatment are offered, which may impede market expansion. Additionally, there are no clinical studies due to insufficient epidemiological data or data regarding the disease, which is preventing the market from expanding throughout the forecast period.

Further, one of the factors driving the market expansion is the increase in healthcare spending, which will boost research into cutting-edge treatments for ailments. Another reason driving the market growth is the increase in patients with paraneoplastic neurological syndrome (PNS). Patients with paraneoplastic neurological syndrome (PNS) frequently exhibit neurologic symptoms either concurrently with the diagnosis of cancer or prior to the discovery of an underlying tumor. However, the growth of the market is anticipated to be hampered by high treatment costs, and challenges securing reimbursements and coverage.

Segmentation Analysis:

The Global Paraneoplastic Cerebellar Degeneration (PCD) Market is segmented on the basis of Diagnosis, Treatment, End User, and Region.

The market is split into three categories based on Diagnosis: imaging test, CSF analysis, paraneoplastic antibody assay. The imaging test segment dominates the market. Growing demand for imaging tests in diagnosis of cerebellar diseases is mainly contributing to segment growth.

The market is segmented into seven categories based on Treatment: immunotherapy, corticosteroids, immunoglobulins, plasma exchange, cyclophosphamide, tacrolimus, and rituximab. The immunotherapy segment dominates the market and is likely to maintain its dominance during the forecast period. This is partly due to a rise in the prevalence of neurological disorders.

The market is segmented into three categories based on end user: cancer research institutes, hospitals, and others. The hospitals segment dominates the market and is likely to maintain its dominance during the forecast period. This is partly due to an increase in the number of patients with Paraneoplastic Cerebellar Degeneration (PCD) is boosting the segment growth.

Competitive Landscape:

The worldwide market for Paraneoplastic Cerebellar Degeneration (PCD) is vastly fragmented in nature which comprised of large and small-sized market players with few large dominating the global market share. The companies in market emphasize on adopting aggressive strategies to reach out large consumer base. Some of the primary techniques used by corporations to strengthen their reach and expand their market share include new Diagnosis launches, partnerships, distribution network development, R&D spending, and mergers and acquisitions.

For instance, in 2022, Novartis AG announced collaboration with Alnylam to expand its neurology therapy related liver functions.

Key features of the study:

This proposed research study on Paraneoplastic Cerebellar Degeneration (PCD) market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2022-2028), considering 2021 as the base year

The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Paraneoplastic Cerebellar Degeneration (PCD) market

The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Paraneoplastic Cerebellar Degeneration (PCD) market

Impact of COVID-19 on Paraneoplastic Cerebellar Degeneration (PCD) market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Paraneoplastic Cerebellar Degeneration (PCD) market post-COVID will also be covered.

In order to give the users of this report a comprehensive view on the Paraneoplastic Cerebellar Degeneration (PCD) market, we have also included competitive landscape and key innovator analysis for the Paraneoplastic Cerebellar Degeneration (PCD) market.

The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.

The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Paraneoplastic Cerebellar Degeneration (PCD) market.

In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.

The global Paraneoplastic Cerebellar Degeneration (PCD) market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PARANEOPLASTIC CEREBELLAR DEGENERATION (PCD) MARKET KEY PLAYERS

Novartis AG

Astellas Pharma Inc.

Abbott

Bristol-Myers Squibb Company

Gilead Sciences, Inc

Glaxosmithkline Plc

F. Hoffmann-La Roche Ltd

Merck Sharp & Dohme Corp.

Sanofi

Pfizer Inc.

Takeda Pharmaceutical

Koninklijke Philips N.V.

General Electric Company

Esaote SpA

NeuroLogica Corporation

Masimo

York Instruments Ltd.

Neusoft Medical Systems

CANON MEDICAL SYSTEMS CORPORATION

GLOBAL PARANEOPLASTIC CEREBELLAR DEGENERATION (PCD) MARKET, BY DIAGNOSIS

Imaging Test

CSF Analysis

Paraneoplastic Antibody Assay

GLOBAL PARANEOPLASTIC CEREBELLAR DEGENERATION (PCD) MARKET, BY TREATMENT

Immunotherapy

Corticosteroids

Immunoglobulins

Plasma Exchange

Cyclophosphamide

Tacrolimus

Rituximab

GLOBAL PARANEOPLASTIC CEREBELLAR DEGENERATION (PCD) MARKET, BY END USER

Cancer Research Institutes

Hospitals

Others

GLOBAL PARANEOPLASTIC CEREBELLAR DEGENERATION (PCD) MARKET, BY REGION

North America

The U.S.

Canada

Europe

Germany

France

Italy

Spain

United Kingdom

Russia

Netherlands

Sweden

Poland

Rest of Europe

Asia Pacific

India

China

South Korea

Japan

Australia

Thailand

Indonesia

Philippines

Rest of APAC

Latin America

Brazil

Mexico

Argentina

Colombia

Rest of LATAM

The Middle East and Africa

Saudi Arabia

United Arab Emirates

Israel

Turkey

Algeria

Egypt

Rest of MEA

TABLE OF CONTENT

1. Paraneoplastic Cerebellar Degeneration (PCD) Market Overview

• 1.1. Study Scope

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Market Snippet by Diagnosis
  • 2.1.2. Market Snippet by Treatment
  • 2.1.3. Market Snippet by End User
  • 2.1.4. Market Snippet by Country
  • 2.1.5. Market Snippet by Region
• 2.2. Competitive Insights

3. Paraneoplastic Cerebellar Degeneration (PCD) Key Market Trends

• 3.1. Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Future Trends

4. Paraneoplastic Cerebellar Degeneration (PCD) Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Paraneoplastic Cerebellar Degeneration (PCD) Market: COVID-19 Impact Analysis

• 5.1. Pre-COVID-19 Impact Analysis
• 5.2. Post-COVID-19 Impact Analysis
  • 5.2.1. Top Performing Segments
  • 5.2.2. Marginal Growth Segments
  • 5.2.3. Top Looser Segments
  • 5.2.4. Marginal Loss Segments

6. Paraneoplastic Cerebellar Degeneration (PCD) Market Landscape

• 6.1. Market Share Analysis, 2021
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Paraneoplastic Cerebellar Degeneration (PCD) Market - By Diagnosis

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Diagnosis, 2021 & 2028 (%)
  • 7.1.2. Imaging Test
  • 7.1.3. CSF Analysis
  • 7.1.4. Paraneoplastic Antibody Assay

8. Paraneoplastic Cerebellar Degeneration (PCD) Market - By Treatment

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Treatment, 2021 & 2028 (%)
  • 8.1.2. Immunotherapy
  • 8.1.3. Corticosteroids
  • 8.1.4. Immunoglobulins
  • 8.1.5. Plasma Exchange
  • 8.1.6. Cyclophosphamide
  • 8.1.7. Tacrolimus
  • 8.1.8. Rituximab

9. Paraneoplastic Cerebellar Degeneration (PCD) Market - By End User

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By Treatment, 2021 & 2028 (%)
  • 9.1.2. Cancer Research Institutes
  • 9.1.3. Hospitals
  • 9.1.4. Others

10. Paraneoplastic Cerebellar Degeneration (PCD) Market- By Geography

• 10.1. Introduction
  • 10.1.1. Segment Share Analysis, By Geography, 2021 & 2028 (%)
• 10.2. North America
  • 10.2.1. Overview
  • 10.2.2. Key Manufacturers in North America
  • 10.2.3. North America Market Size and Forecast, By Country, 2017 - 2028 (US$ Million)
  • 10.2.4. North America Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
  • 10.2.5. North America Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
  • 10.2.6. North America Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.2.7. U.S.
    • 10.2.7.1. Overview
    • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.2.7.3. U.S. Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.2.7.4. U.S. Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.2.7.5. U.S. Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.2.8. Canada
    • 10.2.8.1. Overview
    • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.2.8.3. Canada Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.2.8.4. Canada Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.2.8.5. Canada Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
• 10.3. Europe
  • 10.3.1. Overview
  • 10.3.2. Key Manufacturers in Europe
  • 10.3.3. Europe Market Size and Forecast, By Country, 2017 - 2028 (US$ Million)
  • 10.3.4. Europe Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
  • 10.3.5. Europe Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
  • 10.3.6. Europe Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.3.7. Germany
    • 10.3.7.1. Overview
    • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.3.7.3. Germany Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.3.7.4. Germany Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.3.7.5. Germany Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.3.8. Italy
    • 10.3.8.1. Overview
    • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.3.8.3. Italy Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.3.8.4. Italy Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.3.8.5. Italy Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.3.9. United Kingdom
    • 10.3.9.1. Overview
    • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.3.9.3. United Kingdom Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.3.9.4. United Kingdom Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.3.9.5. United Kingdom Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.3.10. France
    • 10.3.10.1. Overview
    • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.3.10.3. France Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.3.10.4. France Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.3.10.5. France Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.3.11. Russia
    • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.3.11.2. Russia Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.3.11.3. Russia Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.3.11.4. Russia Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.3.12. Netherlands
    • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.3.12.2. Netherlands Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.3.12.3. Netherlands Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.3.12.4. Netherlands Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.3.13. Sweden
    • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.3.13.2. Sweden Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.3.13.3. Sweden Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.3.13.4. Sweden Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.3.14. Poland
    • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.3.14.2. Poland Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.3.14.3. Poland Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.3.14.4. Poland Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.3.15. Rest of Europe
    • 10.3.15.1. Overview
    • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.3.15.5. Rest of the Europe Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
• 10.4. Asia Pacific (APAC)
  • 10.4.1. Overview
  • 10.4.2. Key Manufacturers in Asia Pacific
  • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2017 - 2028 (US$ Million)
  • 10.4.4. Asia Pacific Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
  • 10.4.5. Asia Pacific Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
  • 10.4.6. Asia Pacific Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.4.7. India
    • 10.4.7.1. Overview
    • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.4.7.3. India Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.4.7.4. India Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.4.7.5. India Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.4.8. China
    • 10.4.8.1. Overview
    • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.4.8.3. China Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.4.8.4. China Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.4.8.5. China Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.4.9. Japan
    • 10.4.9.1. Overview
    • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.4.9.3. Japan Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.4.9.4. Japan Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.4.9.5. Japan Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.4.10. South Korea
    • 10.4.10.1. Overview
    • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.4.10.3. South Korea Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.4.10.4. South Korea Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.4.10.5. South Korea Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.4.11. Australia
    • 10.4.11.1. Overview
    • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.4.11.3. Australia Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.4.11.4. Australia Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.4.11.5. Australia Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.4.12. Thailand
    • 10.4.12.1. Overview
    • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.4.12.3. Thailand Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.4.12.4. Thailand Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.4.12.5. Thailand Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.4.13. Indonesia
    • 10.4.13.1. Overview
    • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.4.13.3. Indonesia Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.4.13.4. Indonesia Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.4.13.5. Indonesia Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.4.14. Philippines
    • 10.4.14.1. Overview
    • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.4.14.3. Philippines Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.4.14.4. Philippines Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.4.14.5. Philippines Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.4.15. Rest of APAC
    • 10.4.15.1. Overview
    • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.4.15.3. Rest of APAC Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.4.15.4. Rest of APAC Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.4.15.5. Rest of APAC Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
• 10.5. Latin America
  • 10.5.1. Overview
  • 10.5.2. Key Manufacturers in Latin America
  • 10.5.3. Latin America Market Size and Forecast, By Country, 2017 - 2028 (US$ Million)
  • 10.5.4. Latin America Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
  • 10.5.5. Latin America Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
  • 10.5.6. Latin America Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.5.7. Brazil
    • 10.5.7.1. Overview
    • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.5.7.3. Brazil Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.5.7.4. Brazil Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.5.7.5. Brazil Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.5.8. Mexico
    • 10.5.8.1. Overview
    • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.5.8.3. Mexico Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.5.8.4. Mexico Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.5.8.5. Mexico Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.5.9. Argentina
    • 10.5.9.1. Overview
    • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.5.9.3. Argentina Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.5.9.4. Argentina Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.5.9.5. Argentina Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.5.10. Colombia
    • 10.5.10.1. Overview
    • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.5.10.3. Colombia Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.5.10.4. Colombia Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.5.10.5. Colombia Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.5.11. Rest of LATAM
    • 10.5.11.1. Overview
    • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
• 10.6. Middle East and Africa
  • 10.6.1. Overview
  • 10.6.2. Key Manufacturers in Middle East and Africa
  • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2017 - 2028 (US$ Million)
  • 10.6.4. Middle East and Africa Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
  • 10.6.5. Middle East and Africa Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
  • 10.6.6. Middle East and Africa Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.6.7. Saudi Arabia
    • 10.6.7.1. Overview
    • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.6.8. United Arab Emirates
    • 10.6.8.1. Overview
    • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.6.9. Israel
    • 10.6.9.1. Overview
    • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.6.9.3. Israel Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.6.9.4. Israel Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.6.9.5. Israel Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.6.10. Turkey
    • 10.6.10.1. Overview
    • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.6.10.3. Turkey Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.6.10.4. Turkey Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.6.10.5. Turkey Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.6.11. Algeria
    • 10.6.11.1. Overview
    • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.6.11.3. Algeria Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.6.11.4. Algeria Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.6.11.5. Algeria Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.6.12. Egypt
    • 10.6.12.1. Overview
    • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.6.12.3. Egypt Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.6.12.4. Egypt Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.6.12.5. Egypt Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)
  • 10.6.13. Rest of MEA
    • 10.6.13.1. Overview
    • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
    • 10.6.13.3. Rest of MEA Market Size and Forecast, By Diagnosis, 2017 - 2028 (US$ Million)
    • 10.6.13.4. Rest of MEA Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Million)
    • 10.6.13.5. Rest of MEA Market Size and Forecast, By End User, 2017 - 2028 (US$ Million)

11. Key Vendor Analysis

• 11.1. Competitive Dashboard
• 11.2. Company Profiles
  • 11.2.1. Novartis AG
  • 11.2.2. Astellas Pharma Inc.
  • 11.2.3. Abbott
  • 11.2.4. Bristol-Myers Squibb Company
  • 11.2.5. Gilead Sciences, Inc
  • 11.2.6. Glaxosmithkline Plc
  • 11.2.7. F. Hoffmann-La Roche Ltd
  • 11.2.8. Merck Sharp & Dohme Corp.
  • 11.2.9. Sanofi
  • 11.2.10. Pfizer Inc.
  • 11.2.11. Takeda Pharmaceutical
  • 11.2.12. Koninklijke Philips N.V.
  • 11.2.13. General Electric Company
  • 11.2.14. Esaote SpA
  • 11.2.15. NeuroLogica Corporation
  • 11.2.16. Masimo
  • 11.2.17. York Instruments Ltd.
  • 11.2.18. Neusoft Medical Systems
  • 11.2.19. CANON MEDICAL SYSTEMS CORPORATION

12. 360 Degree Analyst View

13. Appendix

• 13.1. Research Methodology
• 13.2. References
• 13.3. Abbreviations
• 13.4. Disclaimer
• 13.5. Contact Us